KR20240005894A - 항-tmprss6 항체 및 이의 용도 - Google Patents
항-tmprss6 항체 및 이의 용도 Download PDFInfo
- Publication number
- KR20240005894A KR20240005894A KR1020237042253A KR20237042253A KR20240005894A KR 20240005894 A KR20240005894 A KR 20240005894A KR 1020237042253 A KR1020237042253 A KR 1020237042253A KR 20237042253 A KR20237042253 A KR 20237042253A KR 20240005894 A KR20240005894 A KR 20240005894A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- antibody
- tmprss6
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187150P | 2021-05-11 | 2021-05-11 | |
| US63/187,150 | 2021-05-11 | ||
| PCT/US2022/028595 WO2022240877A1 (en) | 2021-05-11 | 2022-05-10 | Anti-tmprss6 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240005894A true KR20240005894A (ko) | 2024-01-12 |
Family
ID=81927373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237042253A Pending KR20240005894A (ko) | 2021-05-11 | 2022-05-10 | 항-tmprss6 항체 및 이의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12448435B2 (https=) |
| EP (1) | EP4337695A1 (https=) |
| JP (1) | JP2024517931A (https=) |
| KR (1) | KR20240005894A (https=) |
| CN (1) | CN117730099A (https=) |
| AU (1) | AU2022274888A1 (https=) |
| BR (1) | BR112023023558A2 (https=) |
| CA (1) | CA3218455A1 (https=) |
| CL (1) | CL2023003331A1 (https=) |
| CO (1) | CO2023016777A2 (https=) |
| IL (1) | IL308375A (https=) |
| MA (1) | MA63064B1 (https=) |
| MX (1) | MX2023013248A (https=) |
| WO (1) | WO2022240877A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022240877A1 (en) | 2021-05-11 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| WO2024211404A2 (en) * | 2023-04-04 | 2024-10-10 | Disc Medicine, Inc. | Anti-tmprss6 antibodies and uses thereof |
| WO2025245434A1 (en) * | 2024-05-24 | 2025-11-27 | Disc Medicine, Inc. | Compositions and methods for treating myelodysplastic syndromes (mds) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CA2991637C (en) | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| KR20220107252A (ko) * | 2019-11-29 | 2022-08-02 | 키맵 리미티드 | 생리학적 철분 과다에 대한 치료 |
| CN115243762A (zh) * | 2020-04-07 | 2022-10-25 | 迈威(美国)生物治疗有限公司 | 抗tmprss6抗体及其用途 |
| WO2022240877A1 (en) | 2021-05-11 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
-
2022
- 2022-05-10 WO PCT/US2022/028595 patent/WO2022240877A1/en not_active Ceased
- 2022-05-10 AU AU2022274888A patent/AU2022274888A1/en active Pending
- 2022-05-10 CA CA3218455A patent/CA3218455A1/en active Pending
- 2022-05-10 EP EP22727583.1A patent/EP4337695A1/en active Pending
- 2022-05-10 BR BR112023023558A patent/BR112023023558A2/pt unknown
- 2022-05-10 CN CN202280047837.4A patent/CN117730099A/zh active Pending
- 2022-05-10 JP JP2023569823A patent/JP2024517931A/ja active Pending
- 2022-05-10 US US17/741,234 patent/US12448435B2/en active Active
- 2022-05-10 MA MA63064A patent/MA63064B1/fr unknown
- 2022-05-10 MX MX2023013248A patent/MX2023013248A/es unknown
- 2022-05-10 IL IL308375A patent/IL308375A/en unknown
- 2022-05-10 KR KR1020237042253A patent/KR20240005894A/ko active Pending
-
2023
- 2023-11-08 CL CL2023003331A patent/CL2023003331A1/es unknown
- 2023-12-04 CO CONC2023/0016777A patent/CO2023016777A2/es unknown
-
2025
- 2025-09-09 US US19/323,318 patent/US20260098084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024517931A (ja) | 2024-04-23 |
| MX2023013248A (es) | 2024-01-29 |
| US20220411487A1 (en) | 2022-12-29 |
| BR112023023558A2 (pt) | 2024-03-12 |
| MA63064A1 (fr) | 2024-02-29 |
| IL308375A (en) | 2024-01-01 |
| CN117730099A (zh) | 2024-03-19 |
| AU2022274888A1 (en) | 2023-12-07 |
| US12448435B2 (en) | 2025-10-21 |
| CO2023016777A2 (es) | 2023-12-11 |
| EP4337695A1 (en) | 2024-03-20 |
| MA63064B1 (fr) | 2025-02-28 |
| CA3218455A1 (en) | 2022-11-17 |
| US20260098084A1 (en) | 2026-04-09 |
| WO2022240877A1 (en) | 2022-11-17 |
| CL2023003331A1 (es) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102831970B1 (ko) | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 | |
| KR102844773B1 (ko) | 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법 | |
| KR102781241B1 (ko) | 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법 | |
| RU2753902C2 (ru) | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 | |
| AU2015348595B2 (en) | T cell activating bispecific antigen binding molecules against FOLR1 and CD3 | |
| KR102161460B1 (ko) | St2 항원 결합 단백질 | |
| KR101963923B1 (ko) | 이중특이적 t 세포 활성화 항원 결합 분자 | |
| KR20220040483A (ko) | 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| KR20210013156A (ko) | 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도 | |
| KR20230017841A (ko) | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| KR20230041819A (ko) | Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도 | |
| KR102724790B1 (ko) | 항 cd147 항체 | |
| KR20150122203A (ko) | T 세포 활성화 이중특이적 항원 결합 분자 | |
| KR20180087430A (ko) | Hla-dr에 특이적으로 결합하는 항체 및 이의 용도 | |
| KR20240005894A (ko) | 항-tmprss6 항체 및 이의 용도 | |
| KR20230017815A (ko) | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 | |
| KR20220140802A (ko) | 항-acvr1 항체 및 이의 용도 | |
| KR20220117300A (ko) | 고형 종양의 치료를 위한 메소텔린-표적화 cd40 작용성 다중특이성 항체 작제물 | |
| US20240150474A1 (en) | Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification | |
| KR20230117379A (ko) | 이종이량체 psma 및 cd3-결합 이중특이적 항체 | |
| CN117242096A (zh) | 结合psma和cd3的异二聚体双特异性抗体 | |
| EA044746B1 (ru) | АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2 | |
| HK40001926B (en) | St2 antigen binding proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231206 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250509 Comment text: Request for Examination of Application |